Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
出版年份 2022 全文链接
标题
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
作者
关键词
-
出版物
Frontline Gastroenterology
Volume -, Issue -, Pages flgastro-2022-102168
出版商
BMJ
发表日期
2022-05-24
DOI
10.1136/flgastro-2022-102168
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial
- (2021) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- (2021) Dan Turner et al. GASTROENTEROLOGY
- Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
- (2021) Sailish Honap et al. DIGESTIVE DISEASES AND SCIENCES
- Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry
- (2021) María Chaparro et al. Journal of Crohns & Colitis
- Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
- (2021) Mathurin Fumery et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy
- (2021) Michele Francesco Chiappetta et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
- (2020) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
- (2020) Aurélien Amiot et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-Analysis
- (2020) Clara Yzet et al. Clinical Gastroenterology and Hepatology
- Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
- (2020) William J Sandborn et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
- (2019) Subrata Ghosh et al. DRUG SAFETY
- The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study
- (2019) Jonathan Blackwell et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis
- (2016) N. To et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1
- (2014) Yaeesh Badat et al. Journal of Crohns & Colitis
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
- (2012) Christina Ha et al. Clinical Gastroenterology and Hepatology
- Tumor necrosis factor-α antagonists and neuropathy
- (2007) Joerg-Patrick Stübgen MUSCLE & NERVE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search